Search research articles
Contact Us
Filters
Showing results (71-80 of 117) with videos related to
Page
of 12
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Alimentary Pharmacology & Therapeutics
|
September 5, 2024
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Journal of Gastroenterology
|
August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices
Fujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.
Alimentary Pharmacology & Therapeutics
|
May 8, 2024
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine
|
January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.
Oncology
|
June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology
|
August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Scientific Reports
|
January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine
|
November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 117) with videos related to
Sort By:
Page
of 12
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Alimentary Pharmacology & Therapeutics
|
September 5, 2024
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Journal of Gastroenterology
|
August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices
Fujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.
Alimentary Pharmacology & Therapeutics
|
May 8, 2024
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Medicine
|
January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.
Oncology
|
June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology
|
August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Scientific Reports
|
January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine
|
November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Page
of 12